TOBI is a brand name for the antibiotic Tobramycin, specifically formulated for inhalation. It is primarily used in the management of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis. TOBI delivers the antibiotic directly to the lungs through a nebulizer, aiming to reduce bacterial load, decrease lung inflammation, and improve respiratory symptoms. This mode of administration allows for high local concentrations of the medication in the lungs while minimizing systemic side effects. TOBI is typically prescribed as part of a comprehensive treatment regimen for cystic fibrosis patients, who are more susceptible to recurrent lung infections. Regular use of TOBI can help to maintain lung function and potentially reduce the frequency of exacerbations related to chronic infections.